Galaria - Empresa Pública de Servizos Sanitarios
Centro asistencial
Hospital Vall d'Hebron
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (15)
2023
-
Effect of Routine Invasive vs Conservative Strategy in Older Adults With Frailty and Non-ST-Segment Elevation Acute Myocardial Infarction: A Randomized Clinical Trial
JAMA Internal Medicine, Vol. 183, Núm. 5, pp. 407-415
-
Large-scale meta-genome-wide association study reveals common genetic factors linked to radiation-induced acute toxicities across cancer types
JNCI Cancer Spectrum, Vol. 7, Núm. 6
2022
-
Impact of operatoŕs experience on peri-procedural outcomes with Watchman FLX: Insights from the FLX-SPA registry
IJC Heart and Vasculature, Vol. 38
-
Overview of health-related quality of life and toxicity of non-small cell lung cancer patients receiving curative-intent radiotherapy in a real-life setting (the REQUITE study)
Lung Cancer, Vol. 166, pp. 228-241
-
The correlation between pre-treatment symptoms, acute and late toxicity and patient-reported health-related quality of life in non-small cell lung cancer patients: Results of the REQUITE study: Symptoms, toxicity and quality of life of lung cancer patients
Radiotherapy and Oncology, Vol. 176, pp. 127-137
-
Treatment time and circadian genotype interact to influence radiotherapy side-effects. A prospective European validation study using the REQUITE cohort
eBioMedicine, Vol. 84
-
Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer
Radiotherapy and Oncology, Vol. 168, pp. 75-82
2021
-
10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer
International journal of radiation oncology, biology, physics, Vol. 111, Núm. 3, pp. S77
-
Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial
Radiotherapy and Oncology, Vol. 160, pp. 115-119
2020
-
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Nature Genetics, Vol. 52, Núm. 1, pp. 56-73
2019
-
Invasive Versus Conservative Strategy in Frail Patients With NSTEMI: The MOSCA-FRAIL Clinical Trial Study Design
Revista Espanola de Cardiologia, Vol. 72, Núm. 2, pp. 154-159
2016
-
Consumption of systemic antifungal agents among acute care hospitals in Catalonia (Spain), 2008-2013
Expert Review of Anti-Infective Therapy, Vol. 14, Núm. 1, pp. 137-144
-
Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial
International Journal of Radiation Oncology Biology Physics, Vol. 96, Núm. 2, pp. 341-348
2015
-
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): A randomised, controlled, phase 3 trial
The Lancet Oncology, Vol. 16, Núm. 3, pp. 320-327
2007
-
Risk factors for candidaemia in critically ill patients: A prospective surveillance study
Mycoses, Vol. 50, Núm. 4, pp. 302-310